Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hofseth Biocare ASA ( (HOFBF) ) has issued an announcement.
Hofseth BioCare ASA’s ProGo® has been recognized for its unique ability to activate GLP-1 and GIP receptors, contributing to weight loss and improved metabolism, as evidenced by clinical studies. This recognition highlights the product’s potential impact on consumer health and medical nutrition, enhancing the company’s market positioning and stakeholder interest.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company focused on consumer and pet health, emphasizing sustainability and optimal use of natural resources. The company upcycles salmon industry by-products into health-improving ingredients such as ProGo®, OmeGo®, and CalGo®, which offer various health benefits including improved metabolism, immune health, and bone and joint support.
Average Trading Volume: 58,711
Current Market Cap: NOK711.2M
See more insights into HOFBF stock on TipRanks’ Stock Analysis page.